Grogan Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۵۰۰۰۰ • واحد: pg/mL

حداقل ۰ — حداکثر ۵ • واحد: ng/mL

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
grogan stage
—stage
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Stage I—
  • Stage II—
  • Stage III—
Direct Clinical Answer

The Grogan Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) calculates stratifying cardiovascular risk, predicting thromboembolic events, or guiding therapeutic interventions. Key inputs include nt probnp. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Classifies prognosis of patients with wild-type transthyretin amyloid cardiomyopathy using cardiac biomarkers NT-proBNP and troponin T

Clinical Indication

The Grogan Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is indicated for bedside clinical practice to support Classifies prognosis of patients with wild-type transthyretin amyloid cardiomyopathy using cardiac biomarkers NT-proBNP and troponin T. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.

Limitations & Contraindications

In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.

Clinical Pearls & Action Plan

Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines. Guideline pearl: Regular reassessment recommended as biomarkers may change with disease progression or treatment.

Formula & Variables:

Stage I: NT-proBNP ≤3000 pg/mL AND Troponin T ≤0.05 ng/mL; Stage II: One biomarker above threshold; Stage III: Both biomarkers above threshold

Input Parameters

NameTypeRequiredDescription
nt_probnpfloatYesN-terminal pro-B-type natriuretic peptide level(pg/mL)
troponin_tfloatYesTroponin T level(ng/mL)

Score Interpretation & Guidance

RangeStageDescription
—Stage IBest prognosis
—Stage IIIntermediate prognosis
—Stage IIIPoor prognosis

Evidence-Based References (EBM)

  • Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014-1020. doi: 10.1016/j.jacc.2016.06.033DOI: 10.1016/j.jacc.2016.06.033
  • Cappelli F, Baldasseroni S, Bergesio F, et al. Biomarker-based staging system for cardiac transthyretin-related amyloidosis. Eur J Heart Fail. 2020;22(11):2187-2196. doi: 10.1002/ejhf.1898DOI: 10.1002/ejhf.1898
  • Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161-172. doi: 10.1016/j.jacc.2016.03.596DOI: 10.1016/j.jacc.2016.03.596

Related calculators